Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 21 Aug, 09:00 pm
BTIG reaffirmed its "Buy" rating for Glaukos, increasing its price target to $202.00 . The company demonstrated strong sales growth, with U.S. glaucoma sales up 64% and Corneal Health revenues climbing 48% . Glaukos raised its 2026 revenue guidance to between $680 million and $70
Walmart (NASDAQ: WMT) Beats Q2 FY2027 Expectations Despite Comparable-Sales Slowdown Walmart Inc. (NASDAQ: WMT) reported strong Q2 FY2027 results, with adjusted earnings per share of $0.81 and revenue of $187.94 billion , both surpassing analyst estimates. The retail giant’
Wolfe Research has significantly increased its price target for Fox Corporation to $93 , signaling a positive outlook for the media giant . The new target suggests a potential 54% upside from the current trading price, surpassing its 52-week high . Fox Corporation maintains a str
Autodesk , a leading design software company, commands a significant market capitalization of approximately $53.06 billion . Despite a recent "Neutral" rating from Citigroup and a daily decline, Autodesk stock has demonstrated strong monthly performance, gaining 15.26% . Investor
Galmed Pharmaceuticals (NASDAQ: GLMD) executed an 8-for-1 reverse stock split on August 19, 2026, consolidating shares without altering total company or investor ownership value. Post-split, Galmed Pharmaceuticals' stock price saw increased activity, crossing its 50-day moving av
Strong Analyst Outlook: Morgan Stanley sets an "Overweight" rating and a $38.00 price target for Keurig Dr Pepper, indicating a potential 22.34% upside from its current trading price of $31.06 . Strategic Acquisition Success: The acquisition of JDE Peet's is driving growth, with
Marvell Technology (NASDAQ: MRVL) Soars on Google AI Chip Deal and Strong Analyst Rating Marvell Technology received an "Overweight" rating from Barclays, signaling strong expected stock performance. The company secured a significant deal with Google (NASDAQ: GOOGL) to supply cus
Unifi, Inc. (NYSE: UFI) Reports Q4 Earnings, Highlights Improving Financial Performance Unifi, Inc. met the analyst consensus estimate with a fiscal fourth-quarter adjusted loss per share of $0.06 , improving from an adjusted loss of $0.56 per share in the prior-year quarter. The
Jaguar Health (NASDAQ: JAGX) Q2 Financials: EPS Beat, Revenue Miss, and Crofelemer Progress EPS Beat: Jaguar Health reported a second-quarter net loss per share of approximately $15.70 , compared with the analyst consensus estimate of a $52.15 loss per share . Revenue Shortfall:
Alpha Cognition (NASDAQ: ACOG) reported significant revenue growth, primarily fueled by its Alzheimer's disease treatment, ZUNVEYL. Analyst firm B. Riley initiated coverage with a "Buy" rating, highlighting the biopharmaceutical company's strong commercial progress. Despite a net
Alvotech (NASDAQ:ALVO) Q2 2026 Earnings: Mixed Financial Performance in Biosimilar Market Alvotech (NASDAQ:ALVO) , a global biotechnology company specializing in biosimilar medicines, reported a mixed Q2 2026, missing analyst consensus for earnings per share but surpassing revenu
KeyBanc upgraded EPR Properties (NYSE:EPR) to Overweight with a $70.00 price target, suggesting a 15.47% upside. The upgrade is driven by strong financial performance, including 15.3% Adjusted Funds From Operations (AFFO) growth and raised full-year 2026 guidance for Funds From O
Carlsberg A/S reported Q3 2026 earnings per share of $0.72 , missing analyst estimates of $0.98 , and revenue of $4.11 billion , slightly below the $4.12 billion estimate. Despite the earnings miss, the company adjusted its full-year profit guidance upwards, supported by strong 7
Wolfspeed (NYSE: WOLF) reported a narrower-than-expected earnings per share (EPS) of -$2.26 , beating analyst estimates. Revenue reached $149.60 million , slightly below estimates but within guidance, driven by its power and materials segments. Strong growth in artificial intelli
Analog Devices (NASDAQ: ADI) received an increased price target from Goldman Sachs, indicating significant upside potential for its semiconductor stock . The company consistently beats earnings and revenue estimates , driven by robust demand for its semiconductor chips in key mar
BILL Holdings (NYSE:BILL) exceeded Q4 earnings and revenue estimates, showcasing robust financial performance. The company is actively transforming into an "AI-native" business, with growing adoption of its AI-powered financial tools. The company maintains a healthy current ratio
Morgan Stanley upgraded Merck (NYSE: MRK) to Overweight with a $179.00 price target, suggesting a 17.6% upside for the pharmaceutical stock . Merck and Moderna (NASDAQ: MRNA) announced successful Phase 3 results for their personalized mRNA cancer vaccine, intismeran autogene, com
Goldman Sachs has increased its price target for Estée Lauder to $112.00 , reaffirming a "Buy" rating for the stock. The company reported a 6% rise in net sales for its fourth quarter, reaching $3.60 billion , alongside a doubling of adjusted EPS to $0.39 . Effective management s
Headlines provided by Investing.com